ArticleAntibodies (Basel, Switzerland)2026
Computational Design and Expression of Headless Influenza Hemagglutinin Antigens Toward a Modular Universal Nanoparticle Vaccine.
Article in Antibodies (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThe elicitation of broadly neutralizing antibodies against conserved antigenic epitopes has been a focus of universal vaccine research. To facilitate immunofocusing on the conserved influenza hemagglutinin (HA) stalk, we designed headless trimeric antigens, initially focusing on subtypes H1, H3, and H5, and subsequently expanding to eight additional HA subtypes.
resultsThe designs were first evaluated in silico; they were predicted to fold correctly by AlphaFold2, and remained stable in molecular dynamics simulations in isolation, as well as bound to a broadly neutralizing antibody. The antigens expressed in HEK293-derived cells in high yields, and eluted predominantly as trimers in SEC-HPLC. Future work will explore the use of mosaic nanoparticles decorated with headless antigens of various subtypes for the optimal elicitation of broadly neutralizing anti-influenza antibodies. Overall, our study advances the use of headless HA trimers as modular antigens toward a universal influenza vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.